SINOVA-M-14041 Human Fatty Acid Binding Protein (h-FABP) Quantitative Test Kit
Clinical Significance:
- Diagnosis of AMI: Plasma FABP levels begin to rise 30 minutes to 3 hours after the onset of AMI, and return to normal within 12 to 24 hours. Therefore, FABP is one of the early diagnostic indicators for AMI with a sensitivity of 78%, which is significantly higher than Myoglobin (Mb) and CK-MB. Thus, FABP is more valuable for the early diagnosis of AMI compared to Mb and CK-MB.
- Other Conditions: Plasma FABP levels can also increase in cases of skeletal muscle injury and renal failure.
Reference Value: <5 µg/L
Indications for FABP Testing:
- Early diagnosis of myocardial infarction (including reinfarction).
- Monitoring the efficacy of thrombolytic therapy.
Product Specifications: 20 tests/box
Product Shelf Life: 18 months when sealed in an aluminum foil pouch. Use within 1 hour after opening the pouch.
Product Storage: Store the test card at 2℃-30℃.
Usage Scenarios:
- Emergency Departments: For early diagnosis of Acute Myocardial Infarction (AMI) and reinfarction, enabling rapid treatment decisions.
- Cardiology Departments: For monitoring the efficacy of thrombolytic therapy in patients with AMI.
- Hospitals and Clinics: For evaluating patients with suspected cardiac events and differentiating between myocardial and skeletal muscle injury.
- Diagnostic Laboratories: For routine testing of FABP levels as part of cardiac health assessments.
Suitable Countries and Regions:
- Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced cardiac diagnostic tools are widely used for improving patient outcomes.
- Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving cardiac diagnostic capabilities and expanding access to modern diagnostic tools.
- Global Health Programs: International health initiatives focused on enhancing cardiac care and improving diagnostic accuracy for myocardial injuries in low-resource settings.
